Orexo's share is listed on NasdaqOMX Stockholm, Sweden (ORX), and is available as American Depository Receipts on OTCQX market in the US (OXROY).
Share price
Name
0.00
0 SEK (0%)
HH:MM CET • 20YY-MM-DD
Latest presentations
Analyst reports
Investment thesis
Latest CEO Comments
NOVEMBER 3, 2021
"Steady progression on our journey to build a broader and stronger Orexo"
Read the latest CEO comments from Nikolaj Sørensen
News flow
Press Releases and News
Orexo provides information about its new proprietary drug delivery platform – amorphOX™
Orexo´s Nomination Committee for the Annual General Meeting 2022
Invitation to presentation of Orexo´s Q3 Interim Report, on November 3 at 1 pm CET
MODIA™ paper published in the Journal of Medical Internet Research Mental Health
Key financial figures
Group net revenue
580 MSEK
Last Twelve Months, Q420-Q321
Group EBITDA
-112 MSEK
Last Twelve Months, Q420-Q321
US Pharma segment EBIT
301 MSEK
Last Twelve Months, Q420-Q321
Cash position
588 MSEK
Q321
